Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia.
暂无分享,去创建一个
Sebastian Uhrig | Mauro Delorenzi | Vaskar Saha | Martin Stanulla | J. Tchinda | M. Loh | R. Collins | M. Delorenzi | M. Muckenthaler | P. Horváth | M. Schrappe | C. Eckert | S. Uhrig | J. Tyner | A. Kulozik | B. Chang | J. Irving | G. Balasubramanian | M. P. Dobay | J. Bourquin | V. Saha | M. Stanulla | A. von Stackelberg | T. Radimerski | O. Bandapalli | J. Kunz | Martin Schrappe | Ernesto Diaz-Flores | Peter Horvath | G. Cario | Jean-Pierre Bourquin | B. Bornhauser | V. Frismantas | R. Meisel | Gunnar Cario | Thomas Radimerski | T. Brown | Viktoras Frismantas | Maria Pamela Dobay | Anna Rinaldi | Joelle Tchinda | Samuel H. Dunn | Joachim Kunz | Paulina Richter-Pechanska | Blerim Marovca | Orrin Pail | Silvia Jenni | Bill H. Chang | Timothy J. Brown | Robert H. Collins | Gnana P. Balasubramanian | Obul R. Bandapalli | Salome Higi | Sabrina Eugster | Pamela Voegeli | Mignon L. Loh | Andreas E. Kulozik | Martina U. Muckenthaler | Julie A. Irving | Roland Meisel | Arend Von Stackelberg | Cornelia Eckert | Jeffrey W. Tyner | Beat C. Bornhauser | Anna Rinaldi | Sabrina Eugster | Blerim Marovca | S. Jenni | P. Voegeli | P. Richter-Pechańska | E. Diaz-Flores | S. H. Dunn | O. Pail | Salome Higi | M. Loh | Thomas Radimerski
[1] S. Armstrong,et al. Patient-derived xenotransplants can recapitulate the genetic driver landscape of acute leukemias , 2016, Leukemia.
[2] P. Houghton,et al. Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia. , 2016, Blood.
[3] A. Letai,et al. Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. , 2016, Cancer discovery.
[4] P. Houghton,et al. A review of new agents evaluated against pediatric acute lymphoblastic leukemia by the Pediatric Preclinical Testing Program , 2016, Leukemia.
[5] M. Schrappe,et al. Activation of concurrent apoptosis and necroptosis by SMAC mimetics for the treatment of refractory and relapsed ALL , 2016, Science Translational Medicine.
[6] Donna Neuberg,et al. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. , 2016, Cancer cell.
[7] A. Moorman. New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia , 2016, Haematologica.
[8] M. Amiot,et al. Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models , 2016, Molecular Cancer Therapeutics.
[9] Joshua M. Korn,et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response , 2015, Nature Medicine.
[10] Thomas Zichner,et al. Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options , 2015, Nature Genetics.
[11] A. Schulz,et al. Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] T. Chambers,et al. BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells. , 2015, Cancer research.
[13] A. Borkhardt,et al. Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment , 2015, Leukemia.
[14] M. Loh,et al. Self-enforcing Feedback Activation between Bcl6 and Pre-b Cell Receptor Signaling Defines a Distinct Subtype of Acute Lymphoblastic Leukemia Self-enforcing Feedback Activation between Bcl6 and Pre-b Cell Receptor Signaling Defines a Distinct Subtype of Acute Lymphoblastic Leukemia Figure 1. Expressi , 2022 .
[15] Krister Wennerberg,et al. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation , 2015, Nature.
[16] Karen Cichowski,et al. Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy , 2015, Cell.
[17] F. Speleman,et al. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. , 2014, Blood.
[18] P. Horváth,et al. Image-based RNA interference screening reveals an individual dependence of acute lymphoblastic leukemia on stromal cysteine support , 2014, Oncotarget.
[19] Heather L. Mulder,et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. , 2014, The New England journal of medicine.
[20] A. Letai,et al. Cell and Molecular Determinants of In Vivo Efficacy of the BH3 Mimetic ABT-263 against Pediatric Acute Lymphoblastic Leukemia Xenografts , 2014, Clinical Cancer Research.
[21] M. Loh,et al. Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. , 2014, Cancer discovery.
[22] C. Eckert,et al. Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. , 2013, Blood.
[23] Krister Wennerberg,et al. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. , 2013, Cancer discovery.
[24] Fatima Al-Shahrour,et al. Niche-based screening identifies small-molecule inhibitors of leukemia stem cells. , 2013, Nature chemical biology.
[25] M. D. Den Boer,et al. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] E. Mejstrikova,et al. Leukemia surfaceome analysis reveals new disease-associated features. , 2013, Blood.
[27] Robert Huether,et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia , 2013, Nature Genetics.
[28] Joseph M. Negri,et al. The role of tumour–stromal interactions in modifying drug response: challenges and opportunities , 2013, Nature Reviews Drug Discovery.
[29] L. Lam,et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets , 2013, Nature Medicine.
[30] Armand Bankhead,et al. Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening. , 2013, Cancer research.
[31] B. Druker,et al. Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia. , 2012, Cancer cell.
[32] S. Rutella,et al. How I treat relapsed childhood acute lymphoblastic leukemia. , 2012, Blood.
[33] S. Ramaswamy,et al. Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.
[34] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[35] R. Arceci. Outcomes after Induction Failure in Childhood Acute Lymphoblastic Leukemia , 2012 .
[36] R. Foà,et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. , 2011, Blood.
[37] A. Letai,et al. Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy , 2011, Science.
[38] K. Parang,et al. Thiazolyl N-benzyl-substituted acetamide derivatives: synthesis, Src kinase inhibitory and anticancer activities. , 2011, European journal of medicinal chemistry.
[39] J. Tchinda,et al. Xenografts of highly resistant leukemia recapitulate the clonal composition of the leukemogenic compartment. , 2011, Blood.
[40] C. Eckert,et al. Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] M. Muckenthaler,et al. Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias , 2011, The Journal of experimental medicine.
[42] Claire Schwab,et al. Acute lymphoblastic leukaemia. , 2011, Methods in molecular biology.
[43] Great,et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial , 2010, The Lancet.
[44] J. V. van Dongen,et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. , 2010, Blood.
[45] B. Schäfer,et al. Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. , 2010, The Journal of clinical investigation.
[46] T. Chou. Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.
[47] M. Liedtke,et al. Therapeutic targeting of MLL. , 2009, Blood.
[48] H. Beverloo,et al. Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia , 2009, Leukemia.
[49] J. Downing,et al. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. , 2007, The Journal of clinical investigation.
[50] Zheng Yang,et al. Dasatinib (BMS-354825) Pharmacokinetics and Pharmacodynamic Biomarkers in Animal Models Predict Optimal Clinical Exposure , 2006, Clinical Cancer Research.
[51] H. Lane,et al. ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors , 2005, Nature Reviews Cancer.
[52] M. D. Boer,et al. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] D. Campana,et al. Development and functional characterization of human bone marrow mesenchymal cells immortalized by enforced expression of telomerase , 2003, British journal of haematology.
[54] M. Cleary,et al. Two types of genomic rearrangements create alternative E2A-HLF fusion proteins in t(17;19)-ALL. , 1994, Blood.
[55] F. Behm,et al. Bone marrow-derived stromal cells prevent apoptotic cell death in B-lineage acute lymphoblastic leukemia. , 1992, Blood.